Reviva Pharmaceuticals Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVPH research report →
Price Chart
About the company
Reviva Pharmaceuticals Holdings, Inc. , a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis.
- CEO
- Laxminarayan Bhat
- IPO
- 2020
- Employees
- 14
- HQ
- Cupertino, CA, US
Get TickerSpark's AI analysis on RVPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.68M
- P/E
- -0.05
- Fwd P/E
- 2.55
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 3.45
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -67.12%
- ROIC
- -18.54%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-20,200,031
- Net Income
- $-19,864,902+33.6%
- EPS
- $-5.48+69.6%
- OCF Growth
- +26.7%
- FCF Growth
- +26.7%
- 52W High
- $15.40
- 52W Low
- $0.26
- 50D MA
- $0.44
- 200D MA
- $0.98
- Beta
- 0.48
- RSI (14)
- 35
- Avg Volume
- 29.02K
No earnings-call transcripts are available for RVPH yet.
- Free Float
- 98.1%
- Shares Outstanding
- 13.11M
- Float Shares
- 12.86M
of shares held by institutions
39 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 3.20M | ▲ 1.27M |
| Nri Wealth Management Lc | 11.38K | ▼ 1.00K |
| Emc Capital Management | 6.70K | ▲ 6.70K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Prabhu Narayan | other | 40,925 |
| Mar 18, 26 | Bhat Laxminarayan | other | 109,150 |
| Mar 18, 26 | Bhat Laxminarayan | other | 40,925 |
| Dec 18, 25 | Funtleyder Leslie D. | other | 8,200 |
| Dec 18, 25 | Margolin Richard A | other | 8,200 |
| Dec 18, 25 | Patel Purav | other | 8,200 |
| Dec 18, 25 | SAXENA PARAG | other | 8,200 |
| Feb 13, 25 | Narayan Prabhu | other | 194,250 |
| Feb 13, 25 | Bhat Laxminarayan | other | 519,000 |
| Feb 13, 25 | Bhat Laxminarayan | other | 181,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RVPH coverage
Recent articles, reports, and earnings notes.
No research on RVPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RVPH report →Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · Nov 12
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
globenewswire.com · Sep 22
Financial Survey: InMed Pharmaceuticals (NASDAQ:INM) & Reviva Pharmaceuticals (NASDAQ:RVPH)
defenseworld.net · Aug 13
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · Aug 12
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
globenewswire.com · Jun 23
Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
globenewswire.com · May 18
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com · May 13
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Moderate Buy” from Analysts
defenseworld.net · Apr 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.